## Indian Market Outlook - 18 October 2021

On the Occasion of Dussehra, the Indian Market remains closed on Friday.

WHO's the technical advisory group will meet on October 26 to consider granting Emergency Use Listing (EUL) to Bharat Biotech's Covaxin, WHO's chief scientist Soumya Swaminathan.

State-run Bank of India on Sunday announced a cut in its interest rates on home and vehicle loans by 35 basis points and 50 basis points, respectively. With this cut, the interest rate on home loans starts at 6.50 percent against earlier 6.85 percent, and at 6.85 percent against 7.35 percent prior on vehicle loans, the bank said in a release.

The Ayurveda firm - the largest in terms of name, brand recall, and revenue - expects to close FY'22 with revenue of over Rs 500 crore, a growth of over 25 percent over the pandemic hit last year and more than double the net income at around Rs 45 crore.

The motor insurance segment, which had a massive decline in FY21, is returning to the growth path, public sector general insurers have been steadily losing ground to the private insurers overall and more so in the bread and butter motor segment, with pie crimping to 32.6 percent in August, down from 36.6 percent a year ago.

Gold imports, which have a bearing on the current account			
deficit, zoomed to about USD 24 billion during April-			
September 2021 due to higher demand in the country,			
according to data from the Commerce Ministry. Imports of			
the yellow metal were USD 6.8 billion in the corresponding			
period last year, the data showed.			

Top Gainers		
Company	Last Price	Change%
ADANIPORTS	812.95	7.11
WIPRO	709.00	5.41
GRASIM	1,754.00	4.59
HDFCBANK	1,687.00	2.90
ITC	256.30	2.85

Top Losers				
Company	Last Price	Change%		
COALINDIA	184.50	-2.92		
TATAMOTORS	496.60	-2.03		
EICHERMOT	2,851.05	-1.88		
HCLTECH	1,246.00	-1.53		
HDFCLIFE	694.40	-0.93		

## Indian Market Outlook - 18 October 2021

## **Disclaimer and General Advice Instructions:**

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing the Corporate Authorized Representative No. CAR No. 001269781 of Laverne Capital Pty Ltd AFSL 482937. The Research Analyst who prepared this report/article hereby certifies that the views expressed in this document accurately reflect the analyst's personal views about the Company and its financial products. The information provided in the Report/Article is provided by Morningstar and FactSet. Laverne Fund is not a fund manager, however, the portfolio and the document is for general advice only, prepared by the Analysts and Research team for our clients.

This report/article have Different Assumptions, Views, Analytical Method of the analyst with no guarantee of reliability and accuracy of the content. The Research Analyst has not been, is not, and will not be receiving direct or indirect compensation for expressing the specific recommendations or views in this report/article. Laverne Securities has its own Research methodology, with regards to the rating and is confirmed by the team for long term Strategic rating of the concerned security as an Investment for Portfolios with High Growth High Risk Profile. Individual Stock is Speculative and of High Risk in nature and strongly

This Document is provided for the Advisors, their Clients, and Financial Professionals for information only and should not be considered an offer or solicitation of an offer to buy or sell a particular security or financial product or instrument.

The information or services provided in this report/article may not be suitable for you and we strongly recommend taking the advice of your Financial Planner or Investment advisors. Laverne Investing will not treat the recipients as its customer by virtue of their receiving the report/article and should seek the advice of their consultant, prior to making any investment decision considering this report/article